CAR-T Approaches for Autoimmune Disorders: Mechanisms, Evidence, and Clinical Perspectives

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy, initially developed for hematological malignancies, is rapidly gaining attention as a potential paradigm-shifting treatment for autoimmune disorders. By leveraging the specificity and cytotoxicity of genetically engineered T cells, CAR-T approaches offer targeted immunomodulation for refractory and severe autoimmune conditions. This review synthesizes recent evidence on the application of CAR-T therapies in autoimmune diseases, elucidating mechanisms, clinical outcomes, risks, and future directions, with the aim of providing clinicians a comprehensive, evidence-based overview of this emerging therapeutic field.

Introduction

The landscape of autoimmune disorder management has evolved considerably in recent decades, with biologics and small molecules providing improved disease control for many patients. However, a subset of individuals with refractory or severe disease remains at significant risk for morbidity and mortality. CAR-T cell therapy, which has revolutionized the treatment of certain hematologic malignancies, is now being investigated as a novel immunotherapeutic strategy for autoimmune diseases. This article comprehensively reviews the scientific rationale, clinical evidence, and practical considerations for the use of CAR-T approaches in the management of autoimmune disorders, with a focus on recent advances and guidelines that inform best practices for clinicians.

Epidemiology / Disease Burden

Autoimmune diseases are characterized by aberrant immune responses against self-antigens, resulting in chronic tissue inflammation and organ dysfunction. These conditions affect up to 5-8% of the population worldwide, with higher prevalence in women and certain ethnic groups. Common autoimmune disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), and type 1 diabetes (T1D), contribute significantly to global disability and healthcare expenditures. Despite advances in immunosuppressive treatments, a considerable proportion of patients experience inadequate response, severe flares, or treatment-related toxicity, underscoring the need for innovative therapies with improved efficacy and safety profiles.

Pathophysiology

Autoimmune disorders arise from a complex interplay of genetic susceptibility, environmental triggers, and immune dysregulation. Central to their pathogenesis is the loss of self-tolerance, leading to the activation of autoreactive lymphocytes and the production of pathogenic autoantibodies and pro-inflammatory cytokines. While conventional therapies target broad immune suppression, CAR-T cell therapy offers a mechanism-based approach that can selectively eliminate pathogenic B or T cells through engineered specificity, potentially restoring immune homeostasis without generalized immunosuppression.

Risk Factors

Risk factors for autoimmune diseases include genetic predisposition (e.g., HLA alleles), female sex, environmental exposures (such as infections, smoking, and certain drugs), hormonal influences, and epigenetic modifications. Patients with a family history of autoimmunity or coexisting autoimmune conditions are at heightened risk. Recognizing these risk factors aids in early diagnosis, risk stratification, and the identification of patients who may benefit from advanced therapies such as CAR-T cell interventions.

Clinical Features

The clinical manifestations of autoimmune diseases are heterogeneous, ranging from mild to life-threatening. Symptoms may include fatigue, fever, joint pain, skin rashes, organ-specific dysfunction (e.g., nephritis, carditis, encephalopathy), and systemic inflammation. Disease courses are often relapsing-remitting or progressive, with flares that can be triggered by infections, stress, or medication changes. Accurate phenotyping is crucial to select appropriate candidates for CAR-T therapy, especially those with refractory disease or severe organ involvement.

Diagnosis

Diagnosis of autoimmune disorders relies on a combination of clinical assessment, serological markers (e.g., ANA, anti-dsDNA, RF, ACPA), imaging studies, and, where indicated, tissue biopsy. Disease activity and damage indices, such as the SLEDAI for lupus or DAS28 for RA, guide therapeutic decisions. In the context of CAR-T therapy, thorough immunophenotyping and assessment of disease refractory status are essential to identify suitable candidates and predict response to treatment.

Treatment & Management

Current management strategies for autoimmune diseases include corticosteroids, conventional disease-modifying antirheumatic drugs (DMARDs), biologic agents targeting cytokines or cell surface molecules, and, in severe cases, plasmapheresis or hematopoietic stem cell transplantation. These approaches are limited by incomplete efficacy, cumulative toxicity, and risk of long-term immunosuppression. CAR-T therapy represents a transformative modality by offering precise elimination of autoreactive immune cells, with the potential for durable remission and reduced treatment burden.

Recent Advances / Emerging Therapies

Recent studies have demonstrated the feasibility and efficacy of CAR-T cell therapy in preclinical models and early-phase clinical trials for autoimmune diseases. For example, anti-CD19 CAR-T cells have shown promise in the treatment of refractory SLE, with reports of complete remission and normalization of serological markers. Similar strategies targeting B-cell antigens are under investigation for multiple sclerosis, pemphigus vulgaris, and other autoantibody-mediated conditions. Innovations such as regulatory T cell (Treg)-based CAR-T constructs and targeted depletion of pathogenic T cell subsets are expanding the therapeutic scope. Safety remains a key concern, with cytokine release syndrome (CRS), neurotoxicity, and long-term immunosuppression being critical risks that require vigilant monitoring and management.

Guideline Recommendations

While CAR-T therapy for autoimmune diseases is not yet standard of care, leading rheumatology and immunology societies acknowledge its potential and recommend consideration in the context of refractory, life-threatening disease unresponsive to conventional therapies. Ongoing clinical trials and real-world evidence will inform future guidelines regarding patient selection, safety monitoring, and long-term management. Multidisciplinary collaboration among rheumatologists, immunologists, hematologists, and cellular therapy specialists is essential to optimize outcomes and mitigate risks.

Conclusion

CAR-T cell therapy represents a groundbreaking advance in the management of severe and refractory autoimmune disorders. By harnessing targeted immunomodulation, this approach offers new hope for patients with limited therapeutic options. Robust clinical trials, long-term safety data, and consensus guidelines are needed to fully define its role in routine clinical practice. As the field evolves, CAR-T therapy is poised to transform the therapeutic landscape of autoimmunity, offering precision intervention and the potential for durable remission in complex diseases.